Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programGiuseppe Procopio, Elena Verzoni, Giacomo Cartenì et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 140
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationSara Lonardi, M. Frisinghelli, Cosimo Rasola et al.|Journal of Clinical Oncology|2023Cited by 41
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with <i>BRAF</i> Mutated MelanomaLorenza Di Guardo, Michele Del Vecchio, Andrea Maurichi et al.|The Oncologist|2021Cited by 10
Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.Francesca Corti, Lorenza Di Guardo, Giovanni Randon et al.|Journal of Clinical Oncology|2020Cited by 4